Chromocell Therapeutics Corp

The Board of the Company appointed Francis Knuettel II as a member of the Board, effective August 12, 2024, to fill an existing vacancy on the Board. Mr. Knuettel will serve on the Board until the next annual meeting of stockholders of the Company and until his successor is elected and qualified, or otherwise, until his earlier death, resignation or removal in accordance with the Company’s bylaws.

Mr. Knuettel, 58, will continue in his roles as the Company’s Chief Executive Officer and President, Chief Financial Officer, Treasurer and Secretary. Biographical information about Mr. Knuettel is contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on April 16, 2024 (the “Annual Report”).

There are no arrangements or understandings between Mr. Knuettel and any other persons pursuant to which he was appointed as a member of the Board. He also advised the Company that he has no family relationships with any director, executive officer or any person nominated or chosen by the Company to become a director or executive officer of the Company. Except as disclosed in the Annual Report, there are no related party transactions involving Mr. Knuettel or any member of his immediate family required to be disclosed pursuant to Item 404(a) of Regulation S-K.